Method for treating diabetes obesity and conditions characterized by increased protein breakdown with novel oxazolidines
First Claim
Patent Images
1. A method of treating disease conditions characterized by an increased protein breakdown, which method comprises administering a pharmaceutically effective amount of a compound of the formula ##STR10## wherein n is the number 1 or 2,T is lower-carbalkoxy,X is phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position or phenyl optionally monosubstituted by fluorine, chlorine, trifluoromethyl or lower-alkoxy,Y is hydrogen or methyl,Z is a group of the formula ##STR11## R1 is lower-alkyl, optionally N-mono-lower-alkylated or N-di-lower-alkylated aminomethyl or a residue --C(O)R2, --C(R3)═
- CH--(CH2)m --C(O)R2, --C(H,R3)--(CH2)m+1 --C(O)R2, --C(H,R3)--(CH2)p --OH or --C(R3)═
CH--C(CH3)═
CH--COOCH3,R11 is hydroxy, lower-alkoxy, lower-alkanoyloxy, sulphamoyl, benzyloxy or phenoxy or a group R1, --O--(CH2)q --OH, --O--(CH2)q --COOR4 ##STR12## R2 is hydroxy, lower-alkyl, lower-alkoxy, dimethylaminoethoxy, lower-alkoxycarbonylethyl or optionally mono-lower-alkylated or di-lower-alkylated amino,R3 is hydrogen or methyl,R4 is lower-alkyl,R5 is hydrogen, lower-alkyl or phenyl optionally para-substituted by chlorine, fluorine, trifluoromethyl, lower-alkyl or lower-alkoxy,R6 is lower-alkyl or phenyl optionally para-substituted by fluorine, chlorine, lower-alkyl or lower-alkoxy,m and p are whole numbers of 0 to 6,v is a whole number of 2 to 4,q and t are whole numbers of 1 to 6, or a physiologically compatible salt thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The oxazolidines of the formula ##STR1## wherein n signifies the number 1 or 2.
T signifies lower carbalkoxy.
X signifies phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position or phenyl optionally monosubstituted by fluorine, chlorine, trifluoromethyl or lower-alkoxy.
Y signifies hydrogen or methyl, and
Z signifies a phenyl or thienyl residue substituted in a defined manner.
and the physiologically compatible salts thereof have catabolic activity and can be used for the treatment of obesity and diabetes mellitus or for the treatment of conditions which are associated with an increased protein breakdown, or as feed additives for fattening animals. They are manufactured starting from corresponding primary amines.
28 Citations
9 Claims
-
1. A method of treating disease conditions characterized by an increased protein breakdown, which method comprises administering a pharmaceutically effective amount of a compound of the formula ##STR10## wherein n is the number 1 or 2,
T is lower-carbalkoxy, X is phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position or phenyl optionally monosubstituted by fluorine, chlorine, trifluoromethyl or lower-alkoxy, Y is hydrogen or methyl, Z is a group of the formula ##STR11## R1 is lower-alkyl, optionally N-mono-lower-alkylated or N-di-lower-alkylated aminomethyl or a residue --C(O)R2, --C(R3)═ - CH--(CH2)m --C(O)R2, --C(H,R3)--(CH2)m+1 --C(O)R2, --C(H,R3)--(CH2)p --OH or --C(R3)═
CH--C(CH3)═
CH--COOCH3,R11 is hydroxy, lower-alkoxy, lower-alkanoyloxy, sulphamoyl, benzyloxy or phenoxy or a group R1, --O--(CH2)q --OH, --O--(CH2)q --COOR4 ##STR12## R2 is hydroxy, lower-alkyl, lower-alkoxy, dimethylaminoethoxy, lower-alkoxycarbonylethyl or optionally mono-lower-alkylated or di-lower-alkylated amino, R3 is hydrogen or methyl, R4 is lower-alkyl, R5 is hydrogen, lower-alkyl or phenyl optionally para-substituted by chlorine, fluorine, trifluoromethyl, lower-alkyl or lower-alkoxy, R6 is lower-alkyl or phenyl optionally para-substituted by fluorine, chlorine, lower-alkyl or lower-alkoxy, m and p are whole numbers of 0 to 6, v is a whole number of 2 to 4, q and t are whole numbers of 1 to 6, or a physiologically compatible salt thereof. - View Dependent Claims (4, 5)
- CH--(CH2)m --C(O)R2, --C(H,R3)--(CH2)m+1 --C(O)R2, --C(H,R3)--(CH2)p --OH or --C(R3)═
-
2. A method of treating diabetes which method comprises administering an effective amount of a compound of formula ##STR13## wherein n is the number 1 or 2,
T is lower-carbalkoxy, X is phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position or phenyl optionally monosubstituted by fluorine, chlorine, trifluoromethyl or lower-alkoxy, Y is hydrogen or methyl, Z is a group of the formula ##STR14## R1 is lower-alkyl, optionally N-mono-lower-alkylated or N-di-lower-alkylated aminomethyl or a residue --C(O)R2, --C(R3)═ - CH--(CH2)m--C(O)R2, --C(H,R3)--(CH2)m+1 --C(O)R2, --C(H,R3)--(CH2)p--OH or --C(R3)═
CH--C(CH3)═
CH--COOCH3,R11 is hydroxy, lower-alkoxy, lower-alkanoyloxy, sulphamoyl, benzyloxy or phenoxy or a group R1, --O--(CH2)q OH, --O--(CH2)q --COOR4 --O--(CH2)q --O--(CH2)t --R5 or ##STR15## R2 is hydroxy, lower-alkyl, lower-alkoxy, dimethylaminoethoxy, lower-alkoxycarbonylethyl or optionally mono-lower-alkylated or di-lower-alkylated amino, R3 is hydrogen or methyl, R4 is lower-alkyl, R5 is hydrogen, lower-alkyl or phenyl optionally para-substituted by chlorine, fluorine, trifluoromethyl, lower-alkyl or lower-alkoxy, R6 is lower-alkyl or phenyl optionally para-substituted by fluorine, chlorine, lower-alkyl or lower-alkoxy, m and p are whole numbers of 0 to 6, v is a whole number of 2 to 4, q and t are whole numbers of 1 to 6, or a physiologically compatible salt thereof. - View Dependent Claims (6, 7)
- CH--(CH2)m--C(O)R2, --C(H,R3)--(CH2)m+1 --C(O)R2, --C(H,R3)--(CH2)p--OH or --C(R3)═
-
3. A method of treating obesity which method comprises administering an effective amount of a compound of formula ##STR16## wherein n is the number 1 or 2,
T is lower-carbalkoxy, X is phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position or phenyl optionally monosubstituted by fluorine, chlorine, trifluoromethyl or lower-alkoxy, Y is hydrogen or methyl, Z is a group of the formula ##STR17## R1 is lower-alkyl, optionally N-amino-lower-alkylated or N-di-lower-alkylated aminomethyl or a residue --C(O)R2, --C(R3)═ - CH--(CH2)m--C(O)R2, --C(H,R3)--(CH2)m+1 --C(O)R2, --C(H,R3)--(CH2)p--OH or --C(R3)═
CH--C(CH3)═
CH--COOCH3,R11 is hydroxy, lower-alkoxy, lower-alkanoyloxy, sulphamoyl, benzyloxy or phenoxy or a group R1, --O--(CH2)q OH, --O--(CH2)q --COOR4 --O--(CH2)q --O--(CH2)t --R5 or ##STR18## R2 is hydroxy, lower-alkoxy, lower-alkoxy, dimethylaminoethoxy, lower-alkoxycarbonylethyl or optionally mono-lower-alkylated or di-lower-alkylated amino, R3 is hydrogen or methyl, R4 is lower-alkyl, R5 is hydrogen, lower-alkyl or phenyl optionally para-substituted by chlorine, fluorine, trifluoromethyl, lower-alkyl or lower-alkoxy, R6 is lower-alkyl or phenyl optionally para-substituted by fluorine, chlorine, lower-alkyl or lower-alkoxy, m and p are whole numbers of 0 to 6, v is a whole number of 2 to 4, q and t are whole numbers of 1 to 6, or a physiologically compatible salt thereof. - View Dependent Claims (8, 9)
- CH--(CH2)m--C(O)R2, --C(H,R3)--(CH2)m+1 --C(O)R2, --C(H,R3)--(CH2)p--OH or --C(R3)═
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeHoffmann-La Roche Incorporated (Roche Holding AG)
-
Original AssigneeHoffmann-La Roche Incorporated (Roche Holding AG)
-
InventorsMuller, Marcel, Alig, Leo
-
Primary Examiner(s)TSANG, CECILIA J
-
Application NumberUS07/152,522Time in Patent Office606 DaysField of Search544/367, 514/252, 514/376US Class Current514/376CPC Class CodesC07D 263/04 having no double bonds betw...C07D 263/06 with hydrocarbon radicals, ...C07D 333/38 Carbon atoms having three b...C07D 409/06 linked by a carbon chain co...C07D 413/06 linked by a carbon chain co...
